Haemonetics (HAE) has been on a downward spiral lately with significant selling pressure. After declining 11.8% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock i ...

Investors with an interest in Medical - Products stocks have likely encountered both Haemonetics (HAE) and Stryker (SYK) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision ...

If approved, garadacimab will be the first and only once-monthly treatment inhibiting factor XIIa to prevent attacks in HAE patients – a community CSL has been serving for more than 40 yearsMARBURG, Germany, Dec. 13, 2024 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending granting a marketing authorization for garadacimab as a once-monthly p ...

Haemonetics (HAE) closed the last trading session at $85.26, gaining 13.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $109 indicates a 27.8% upside potential.The average comprises eight short-term price targets ranging from a low of $85 to a high of $125, with a standard deviation of $13.11. While the lowest estimate indicates a decline of 0.3% from the current price level, th ...

Haemonetics Corporation (HAE) recently entered into a definitive agreement with GVS, S.p.A ("GVS") to sell its whole blood assets. Haemonetics intends to use the proceeds from this transaction for general corporate purposes and additional investments in growth initiatives.The transaction comprises a total cash consideration of up to $67.1 million, which includes $44.6 million in upfront and up to $22.5 million in contingent earn-outs over the next four years. HAE’s Likely Stock Trend Following the NewsSubse ...

BOSTON, Dec. 3, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced that it has entered into a definitive agreement to sell its whole blood assets to GVS, S.p.A ("GVS"), one of the world's leading manufacturers of filter solutions for applications in the healthcare and life sciences sectors. The transaction comprises a total cash consideration of up to $67.1M, which ...

Shares of Haemonetics (HAE) have gained 16.6% over the past four weeks to close the last trading session at $87.42, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $109.78 indicates a potential upside of 25.6%.The average comprises nine short-term price targets ranging from a low of $85 to a high of $125, with a standard deviation of $12.49. While the lowest estimate indicates a ...

Haemonetics Corporation (HAE) delivered adjusted earnings per share (EPS) of $1.12 in the second quarter of fiscal 2025, up 13.1% year over year. The bottom line surpassed the Zacks Consensus Estimate by 2.8%.On a GAAP basis, the EPS was 66 cents compared with 48 cents in the prior-year quarter.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Following the earnings announcement on Nov. 7, shares of HAE increased 1% in Friday’s session, finishing at $87.42.HAE’s Q2 Total RevenuesRevenue ...

Financial Data and Key Metrics - Q2 revenue was $346 million, a 9% reported growth and 4% organic growth, primarily driven by the hospital business [7] - Year-to-date revenue growth was 8% reported and 3% organic [7] - Q2 adjusted EPS was $1.12, a 13% increase YoY [7] - Adjusted gross margin reached 56.7%, up 270 basis points YoY, with 70% of the improvement driven by volume and mix [30] - Adjusted operating income was $83.5 million, up $15 million, reflecting a 310 basis point sequential expansion [33] - Adjusted net income was $57.3 million, up $7 million or 13% YoY [36] - Free cash flow was $20.4 million, compared to $84.8 million in fiscal 2024 [41] Business Unit Performance - Plasma revenue declined 3% in Q2 and year-to-date, primarily due to CSL's planned transition [10] - Software revenue was flat in Q2 but grew 10% year-to-date, driven by NexLynk DMS upgrades [11] - Hospital revenue grew 31% reported and 16% organic in Q2, driven by Blood Management Technologies and TEG growth [17][18] - Interventional Technologies grew 61% in Q2 and 64% year-to-date, driven by the successful launch of VASCADE MVP XL [20][21] - Newly acquired products contributed $16 million in Q2 and $34 million year-to-date [23] Market Performance - North America disposables revenue declined 3% in Q2, primarily due to CSL's transition [10] - Europe showed strong collections momentum, with recent volume pressures considered transitory [11] - China faced market challenges, particularly in TEG 5000 pricing, contributing to a 5% corporate revenue share [75] Strategic Direction and Industry Competition - The company is upgrading its NexSys platform and accelerating technology upgrades across U.S. centers, expecting completion this fiscal year [12] - The company is gaining market share in plasma collection and converting competitors' centers with its enhanced NexSys platform [13] - The company is expanding its presence in the rapidly growing pulsed field ablation market with VASCADE MVP XL [21] - The company is focusing on expanding its market share in electrophysiology and building a foundation in interventional cardiology and structural heart [25] Management Commentary on Operating Environment and Future Outlook - The company reaffirmed its total revenue growth expectation for fiscal 2025 in the range of 5% to 8% and raised organic growth guidance to 1% to 4% [9] - The company expects a return to more rapid plasma collections in the near to intermediate term, driven by strong end-market demand for Ig therapies [14] - The company raised its organic revenue growth guidance for the Hospital business to 14% to 17% [26] - The company remains confident in achieving short- and long-term goals, navigating complex market challenges, and adapting to emerging trends [28] Other Important Information - The company entered into an accelerated share repurchase agreement to buy back $75 million of common stock [39] - The company has $150 million remaining under its existing share repurchase authorization [40] - The company expects working capital to improve in the second half of the year and reaffirmed its free cash flow guidance for fiscal 2025 at $130 million to $180 million [43] Q&A Session Summary Question: Adoption and pricing dynamics of VASCADE MVP XL - VASCADE MVP XL has been introduced in nearly half of the existing accounts, with strong feedback on ease of use and functionality [53] - The company expects high 20% growth in the second half of the year, driven by continued penetration and pricing reflecting the value proposition [54][55] Question: Plasma business dynamics excluding CSL - Excluding CSL, the plasma business grew on pricing, driven by technology upgrades, despite a mild pullback in volumes [57][58] Question: Adjusted operating margin and cost-cutting - The company expects flattish operating margins in Q3, with a bump in Q4, driven by mix improvements and investments in clinical teams [64][65] Question: Acquired products in the Hospital segment - The company remains bullish on acquired products, with slower-than-expected progress due to market dynamics, particularly in PFA [67][68] Question: TEG market performance - TEG growth was strong in the U.S. and Europe, driven by the heparinase neutralization cartridge, while China faced pricing challenges [74][75] Question: VASCADE growth trajectory - The company expects continued accelerated growth for VASCADE, driven by market penetration and international expansion [87][88] Question: Blood Center margin stability - The company is focusing on margin expansion in the Blood Center business, particularly in the plasma collections segment [91][92] Question: Clinical investments and OpSens rollout - The company is making clinical investments to support growth, particularly in the OpSens and VASCADE product lines [97][98] Question: International launch of VASCADE - The company is ahead of schedule in Japan and building momentum in Europe, with international expansion being a key growth driver [102][103] Question: Plasma share gains - The company expects to gain momentum in plasma share gains moving into FY 2026, driven by technology upgrades [105][106] Question: VASCADE MVP XL labeling expansion - The company is working on expanding the label for VASCADE MVP XL, with FDA support expected [110][112] Question: Currency impact on margins - Currency is expected to remain a headwind in the second half of the year, depending on prevailing rates [113] Question: CSL contribution - CSL is expected to contribute approximately $100 million in fiscal 2025, with 70% already realized in the first half [114] Question: M&A strategy - The company's immediate priority is delivering on recent acquisitions, with a focus on tuck-in acquisitions and opportunistic share buybacks [117][118]

Haemonetics (HAE) reported $345.51 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 8.6%. EPS of $1.12 for the same period compares to $0.99 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $343.02 million, representing a surprise of +0.73%. The company delivered an EPS surprise of +2.75%, with the consensus EPS estimate being $1.09.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wal ...